NewDetail

AICEP
Agência para o Investimento e Comércio Externo de Portugal

CABEÇALHO

The most innovative bioeconomy CEO 2020 is Simão Soares, CEO of SilicoLife, the Portuguese company founded in 2010 which designs optimized microorganisms and novel pathways for industrial biotechnology applications.

“Based on metabolic engineering and synthetic biology approaches, the company shortens the development time and costs of new highly effective processes for the production of specific target compounds such as chemicals, food ingredients or biopolymers.” Soares succeeds to Ken Richards (Leaf Resources), Tony Duncan (Circa Group), Jürgen Eck (BRAIN AG) and Alex Michine (MetGen), respectively most innovative CEO 2016, 2017, 2018 and 2019.

 

We heartily congratulate him on this important recognition and sincerely thank our readers for the great participation in the survey. As usual, we would like to underline that the bioeconomy revolution is a reality thanks to visionary managers like Soares, the other nine selected along with him in the list of the 10 most innovative bioeconomy CEOs and to all those who in different roles contribute to research, develop and commercialize new bio-based products.

 

About the winner:

Simão Soares is an engineer seduced by the enormous transformational potential in the Industrial Biotechnology world. He holds a MSc in Bioinformatics from the University of Minho, postgraduate in management from NOVA School of Business and Economics and trained in Blue Ocean Strategy at INSEAD. Simão was a visiting researcher at the Technical University of Denmark, in the integration of omics data with genome scale models, and also collaborated with the University of Minho in the fields of Bioinformatics and Systems Biology, with published work in computational biology top ranked journals.
After some years of training and research in the academia, Simão became CEO of SilicoLife, a company working in the powerful combination of artificial intelligence and biological knowledge to design optimized microbial strains for the cost-effective production of specific target compounds such as biofuels, chemicals, food ingredients or biopolymers. He is also consultant for international organizations in industrial biotechnology topics and has an extended experience in managing in silico metabolic engineering projects for industrial biotechnology clients.

Partilhar